Attn: Trading and Market Making/Legal and Compliance/Operations/Systems
UNIFORM PRACTICE ADVISORY (UPC #88-26) 11/10/2026 Biolase Inc (BIOLQ)

Notice has been received that the above Company's Amended Combined Joint Chapter 11 Plan of Liquidation and Disclosure Statement became effective on 11/06/2026. Pursuant to the plan, On the Plan Effective Date, all Interests in the Debtors shall be cancelled, and the Holders of Interests shall receive no Distribution under the Plan.[1]

Members are reminded of their obligations under FINRA Rule 2111 if they continue to engage in transactions in the above security after the effective date.

Pursuant to FINRA Rule 11530, members are advised that, among other things, in contracts for securities where a public announcement or publication of general circulation discloses that the securities have been deemed worthless, deliveries shall consist a) the worthless securities or; or b) a Letter of Indemnity which shall grant the purchaser any rights and privileges which might accrue to the holders of the physical securities. Such deliveries shall operate to close-out the contract and shall be settled at the existing contract price pursuant to FINRA Rule 11530.

Questions regarding this notice should be directed to: FINRA Market Operations- 1-866-776-0800.

[1] *See e.g., In re:* Biolase Inc., et al., Debtors. Chapter 11 Case No. 24-12245 (KBO) Amended Combined Joint Chapter 11 Plan of Liquidation and Disclosure Statement of Biolase Inc and its Debtor Affiliates

9509 Key West Avenue
Rockville, MD
20850-3329
t 240 386 4000
www.finra.org